dr. eradat on rituximab biosimilar in cd20 b-cell nhl and cll
Published 4 years ago • 308 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
2:15
dr. danilov on utility of rituximab biosimilars in cll
-
21:17
new anti-cd20 antibodies for cll - are they better than rituximab?
-
1:27
dr. mcbride on biosimilar rituximab
-
2:32
chc 2018: dr. david macdonald - anti-cd20 in 2018
-
6:00
anti-cd20 antibodies
-
13:21
rituximab | anti-cd20 antibody | anticancer drugs
-
1:41
rituximab responses and cd4 t cell depletion
-
2:29
combo of rg6146/venetoclax/rituximab for r/r dlbcl: initial data
-
1:22
first-in-human study of tg-1801, a cd19/cd47 bispecific antibody ± ublituximab in bcl
-
3:16
how will biosimilars save us money?
-
2:04
time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
3:26
selecting between anti-cd20 bispecific antibodies and anti-cd19 car t-cells in third-line nhl
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
2:55
everolimus and itacitinib in patients with hl r/r to brentuximab vedotin and checkpoint inhibitors
-
1:01
dr. kochenderfer discusses the b-cell antigen cd19
-
3:36
ukall14: rituximab dose & reduced intensity transplant in b-all & nelarabine consolidation in t-all
-
2:47
cc-99282 ± rituximab for r/r nhl: phase i/ii trial interim analysis
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial